Skip to main content

Cardiol Therapeutics Inc(CRDL-T)
TSX

Today's Change
Real-Time Last Update

Cardiol Therapeutics Inc

2265 Upper Middle Road East
Suite 602
Oakville ON L6H 0G5 CAN
P: 289-910-0850
https://www.cardiolrx.com

Sectors & Indices

Sector
Industry
Employees

Profile

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Key Executives

NameTitle
Christopher J. WaddickCFO/Director/Secretary
David G. ElsleyCEO/Director/President
Andrew HamerChief Medical Officer/Other Corporate Officer
Bernard LimCOO

More from The Globe

Analysts’ forecast returns, recommendations and yields for all stocks in the S&P/TSX SmallCap Index
The S&P TSX composite index screen at the TMX Market Centre in Toronto is photographed on Friday, November 11, 2022.
Small caps to watch: Aecon, Maple Leaf Foods, Tecsys and more
Packages of Maple Leaf Foods chicken breasts are shown on a shelf at a grocery store in Oakville, Ont., Friday, Jan.6, 2023.
Thursday’s analyst upgrades and downgrades
A pumpjack operates at the Vermilion Energy site in Trigueres, France, June 14, 2024.
Wednesday’s analyst upgrades and downgrades
A Pet Valu store is pictured in Ottawa, Tuesday, Sept. 13, 2022.
number cruncher
Seven Canadian oil producers set to benefit from rising prices
For Number Cruncher column in Globe Investor/ROB only.
Bullish on Mullen Group Ltd.
Monica Rizk
Top non-resource stocks on the TSX with strong insider signals
Ted Dixon
Berkshire Hathaway shares have largest slide since Buffett’s resignation
FILE PHOTO: A screen displays the trading information for Berkshire Hathaway inc. as traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., October 22, 2025. REUTERS/Brendan McDermid/File Photo

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Financial data provided by Zacks Investment Research.